Next Level Life Science - Automated Modeling and Simulation with Devops & Cloud
Tuesday, May 31, 2022 9:00 AM to 6:30 PM · 9 hr. 30 min. (Europe/Berlin)
Foyer 3 + H - Ground Floor
HPC Workflows
Information
Cloud-based modeling under GCP (Good Clinical Practices) requires a scalable HPC infrastructure that can handle the high computational demands of complex simulations of virtual patients in clinical trials. GNS Systems supported the international pharmaceutical company Bayer to fully automate a cloud project according to the Infrastructure as Code principle in the build, test and deployment parts in Microsoft Azure. Nodes are scaled automatically via CycleCloud. The infrastructure of the individual environments is rolled out using a fully automated CI/CD pipeline.
The joint cloud project of GNS Systems and Bayer shows a successful example of a fully automated modeling and simulation environment in the cloud. Despite a clear separation of the environments (development, validation, production), it was possible to accelerate the development and adaptation of the simulation infrastructure with the help of a restructuring of the code repositories and modularization. Automatically scalable cloud resources are the key to efficient pharmacokinetic-pharmacodynamic modeling of virtual patients in clinical R&D projects at Bayer. Based on this - drug development initiatives can be noticeably accelerated which with good chance has an important influence on the health of future patients.
Contributors:
The joint cloud project of GNS Systems and Bayer shows a successful example of a fully automated modeling and simulation environment in the cloud. Despite a clear separation of the environments (development, validation, production), it was possible to accelerate the development and adaptation of the simulation infrastructure with the help of a restructuring of the code repositories and modularization. Automatically scalable cloud resources are the key to efficient pharmacokinetic-pharmacodynamic modeling of virtual patients in clinical R&D projects at Bayer. Based on this - drug development initiatives can be noticeably accelerated which with good chance has an important influence on the health of future patients.
Contributors:
- Christopher Woll (GNS Systems GmbH)
- Björn Willenberg (GNS Systems GmbH)
Format
On-site
